Multidisciplinary Use of PSMA PET in Advanced Prostate Cancer

In this episode, ‘Multidisciplinary Use of PSMA PET in Advanced Prostate Cancer,’ the panelists explore how PSMA PET imaging is ordered, interpreted, and integrated into patient management across specialties. Urologists, medical oncologists, nuclear medicine physicians, radiologists, and radiation oncologists all play important roles, with ordering and interpretation responsibilities often varying by practice setting. In many cases, imaging findings are reviewed collaboratively—either in formal multidisciplinary tumor boards or through sequential communication among specialists—to guide staging and treatment decisions. Challenging or discordant cases, particularly when imaging findings do not align with clinical risk factors, frequently prompt closer cross-specialty discussion. The conversation highlights the growing reliance on PSMA PET as a primary imaging modality and the evolving shift away from conventional imaging, while emphasizing the importance of coordinated, patient-centered decision-making.

The next episode in this series, ‘Expanding Clinical Use of PSMA PET in Advanced Prostate Cancer,’ examines the evolving role of PSMA PET imaging in guiding treatment decisions, monitoring response, and assessing progression in advanced prostate cancer. As evidence grows, clinicians are increasingly using PSMA PET beyond its original staging indications, sometimes extending beyond formal guideline and label recommendations.